Article Text
PDF
Abstract
Introduction/Background Uterine sarcomas are rare and aggressive gynaecological malignancies. The aim of this study is to evaluate the epidemiology, treatment outcomes and survival rates of uterine sarcoma patients managed at our institute.
Methodology The medical records of patients with histology-proven uterine sarcoma, including leiomyosarcoma (LMS), adenosarcoma (ADS) and endometrial stromal sarcoma (ESS), treated at our institution between February 2010 and February 2022 were analyzed. Clinicopathological variables and treatment strategies were assessed, and overall survival (OS) and disease-free survival (DFS) rates were evaluated.
Results Of the total 41 patients with uterine sarcomas, 60.9% (25/41) were found to have LMS, 19.5% (8/41) had ADS and 19.5% (8/41) had ESS. The mean age was 56.8 years and the median follow-up time was 51.4 months. Vaginal bleeding (35%) or pelvic mass symptoms (41%) were the most common presenting symptoms. In a few cases, sarcoma was only detected after primary surgery for a presumed benign cause. Out of the 25 patients with LMS, 72% (18) were suitable for, and had surgical management as per the BGCS (British Gynaecology Cancer Society) consensus. 44% of surgically managed patients also received chemotherapy. The most common chemotherapy agents used were - Gemcitabine, docetaxel, doxorubicin and Ifosfamide. 70% of recurrences were treated surgically. The pelvis was the most common site of recurrence (70%). The median OS, PFS (Progression-free survival) and DFS for the LMS group were 25, 8(n=21) and 44.5 months(n=9), respectively. The 5-year survival rate for LMS, ADS and ESS groups was 30.5%, 100% and 37.5% respectively. The 5-year survival for LMS was found to be significantly worse than other histology types (Log-rank 0.016).
Conclusion Our study observed a significant association between tumour histological types, tumour stage and OS. Our study provides valuable data for the ongoing evaluation of treatment strategies and survival trends among these incredibly rare cancers.
Disclosures None.
